Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Watts

Sports Medicine Abilene, TX Doctor of Osteopathy

NPI 1285600684 CMS profile 103773

1749 Pine St, Abilene, TX 79601

Open in the dashboard

General payments

$4,037

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Watts of Abilene, TX is reported in the CMS Open Payments database as having received $4,037 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $453 12
2024 General $367 9
2023 General $228 5
2022 General $842 14
2021 General $364 14
2020 General $1,197 31
2019 General $586 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Watts
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Paul Watts were reported at $453. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Paul Watts Sports Medicine median Middle half National median
2019 $586 $119 $35–$362 $163
2020 $1,197 $77 $24–$275 $114
2021 $364 $104 $28–$340 $132
2022 $842 $94 $31–$272 $149
2023 $228 $91 $34–$271 $160
2024 $367 $126 $38–$294 $164
2025 $453 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,747 41 payments
  2. Boston Scientific Corporation $986 11 payments
  3. Collegium Pharmaceutical, Inc. $292 24 payments
  4. Flexion Therapeutics, Inc. $269 23 payments
  5. Allergan Inc. $162 10 payments
  6. SI-BONE, Inc. $144 2 payments
  7. Avanos Medical $111 2 payments
  8. Vertex Pharmaceuticals Incorporated $99 2 payments
  9. Ge Healthcare $97 1 payment
  10. Horizon Therapeutics plc $42 3 payments
  11. Other $89 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,082 111 payments
  2. Travel and Lodging $920 7 payments
  3. Education $35 5 payments
Products named General payments · program years 2019–2025
  1. SUPERION Pain Management $778 8 payments
  2. PROCLAIM Neuromodulation $676 8 payments
  3. OCTRODE Neuromodulation $451 13 payments
  4. XTAMPZA $282 22 payments
  5. Zilretta $269 23 payments
  6. Proclaim Family of SCS IPGs $253 8 payments
  7. OCTRODE Structural Heart $204 7 payments
  8. UBRELVY $162 10 payments
  9. PROCLAIM Neuromodulation $118 2 payments
  10. Superion Pain Management $110 2 payments
  11. Other $531 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

4,201

Median for Family Practice: 1,826

Drug cost

$186,873

Median for Family Practice: $120,094

Branded share of claims

62.6%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 2,053 $62,806
Fentanyl Generic 386 $40,781
Oxycontin Oxycodone Hcl Brand 24 $30,912
Hydrocodone Bitartrate Er Hydrocodone Bitartrate Brand 21 $12,111
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 184 $6,001
Xtampza Er Oxycodone Myristate Brand 14 $4,792
Gabapentin Generic 391 $4,730
Acetaminophen-Codeine Acetaminophen With Codeine Brand 111 $4,360
Morphine Sulfate Er Morphine Sulfate Brand 93 $3,776
Oxymorphone Hcl Er Oxymorphone Hcl Brand 12 $3,571

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$188,066

Of which drugs: $3,002

Medicare patients

526

Average age 74

Services billed

3,103

331 women, 195 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 36%
Diabetes 35%
Depression 28%
Chronic kidney disease 25%
Osteoporosis 23%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 67 458 $332

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record